Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 5/20 | 0.76 |
| ▸ | HRH1 | P35367 | 4/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.76 |
| ▸ | USP2 | O75604 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.76 |
| ▸ | HRH2 | P25021 | 2/20 | 0.76 |
| ▸ | HTR2A | P28223 | 2/20 | 0.76 |
| ▸ | HTR2B | P41595 | 2/20 | 0.76 |
| ▸ | DRD2 | P14416 | 2/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.76 |
| ▸ | DRD4 | P21917 | 1/20 | 0.76 |
| ▸ | HTR7 | P34969 | 1/20 | 0.76 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.76 |
| ▸ | HTR5A | P47898 | 1/20 | 0.76 |
| ▸ | HTR6 | P50406 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13845055 | 1.00 | DRD3 (0.76) | DRD3HRH1KCNH2CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL5113093 | 0.99 | DRD3 (0.74) | DRD3HRH1KCNH2CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL6475984 | 0.97 | DRD3 (0.73) | DRD3HRH1KCNH2CHRM2ADRA2A | |
| SCHEMBL7282583 | 0.94 | HRH1 (0.67) | DRD3HRH1KCNH2CHRM2ADRA2A | |
| SCHEMBL1491229 | 0.91 | OPRD1 (0.65) | DRD3HRH1KCNH2CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL27914610 | 0.89 | OPRD1 (0.64) | DRD3HRH1KCNH2CHRM2ADRA2A | |
| SCHEMBL7670965 | 0.88 | DRD3 (0.72) | DRD3HRH1KCNH2CHRM2ADRA2A | |
| SCHEMBL29175114 | 0.88 | HRH1 (0.67) | DRD3HRH1KCNH2CHRM2ADRA2A | |
| SCHEMBL29175113 | 0.88 | HRH1 (0.67) | DRD3HRH1KCNH2CHRM2ADRA2A | |
| Hydroxyzine SCHEMBL383277 | 0.87 | DRD3 (1.00) | DRD3HRH1KCNH2CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012175642-A1 | PEPTIDE PRODRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-12-27 | — | — | WO | claimed |
| US-20110172425-A1 | NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES | CALYX CHEMICALS AND PHARMACEUTICALS PVT. LTD. (IN) | 2011-07-14 | — | — | US | claimed |
| WO-2010046908-A2 | NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES | CALYX CHEMICALS AND PHARMACEUTICALS PVT. LTD. (IN) | 2010-04-29 | — | — | WO | claimed |
| US-20090030205-A1 | Process for obtaining cetirizine dihydrochloride | COSMA S.P.A. | 2009-01-29 | — | — | US | claimed |
| EP-2019096-A1 | Process for obtaining Cetirizine dihydrochloride | Cosma S.p.A. (IT) | 2009-01-28 | — | — | EP | claimed |
| US-20060258684-A1 | 2-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride as anti-allergenic compound and process for its production | WOCKHARDT LIMITED (IN) | 2006-11-16 | — | — | US | claimed |
| EP-1628964-A1 | 2-[2-[4-[(4-CHLOROPHENYL) PHENYLMETHYL] -1-PIPERAZINYL] ETHOXY] ACETIC ACID MONOHYDROCHLORIDE AS ANTI-ALLERGENIC COMPOUND AND PROCESS FOR ITS PRODUCTION | Wockhardt Limited (IN) | 2006-03-01 | — | — | EP | claimed |
| WO-2004103982-A1 | 2-[2-[4-[(4-CHLOROPHENYL) PHENYLMETHYL]-1-PIPERAZINYL]ETHOXY]ACETIC ACID MONOHYDROCHLORIDE AS ANTI-ALLERGENIC COMPOUND AND PROCESS FOR ITS PRODUCTION | WOCKHARDT LIMITED (US) | 2004-12-02 | — | — | WO | claimed |
| EP-1233954-B1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2004-10-20 | — | — | EP | claimed |
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | EGIS GYOGYSZERGYAR RT. (HU) | 2003-05-15 | — | — | US | claimed |
| EP-1233954-A1 | A PROCESS FOR THE PREPARATION OF 2- 4-(ALPHA-PHENYL-P-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGIS GYOGYSZERGYAR RT. (HU) | 2002-08-28 | — | — | EP | claimed |
| WO-2001040211-A1 | A PROCESS FOR THE PREPARATION OF {2-[4-(α-PHENYL-p-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY}ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR | EGIS Gyógyszergyár Rt. (HU) | 2001-06-07 | — | — | WO | claimed |
| EP-2731594-B1 | CAPSULE FORMULATION COMPRISING MONTELUKAST AND LEVOCETIRIZINE | HANMI PHARM IND CO LTD (KR) | 2019-04-24 | — | — | EP | disclosed |
| US-9801876-B2 | Complex granule formulation having improved stability comprising levocetirizine and montelukast | HANMI PHARM. CO., LTD (KR) | 2017-10-31 | — | — | US | disclosed |
| US-9801876-B2 | Complex granule formulation having improved stability comprising levocetirizine and montelukast | HANMI PHARM. CO., LTD (KR) | 2017-10-31 | — | — | US | disclosed |
| US-20160367551-A1 | COMPLEX GRANULE FORMULATION HAVING IMPROVED STABILITY COMPRISING LEVOCETIRIZINE AND MONTELUKAST | HANMI PHARM. CO., LTD (KR) | 2016-12-22 | — | — | US | disclosed |
| WO-2001029016-A1 | PROCESS FOR PREPARING PIPERAZINE-SUBSTITUTED ALIPHATIC CARBOXYLATES | SALSBURY CHEMICALS, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| US-6140501-A | CHEMICAL INTERMEDIATES | UCB, S.A. (BE) | 2000-10-31 | — | — | US | disclosed |
| WO-2000052000-A1 | A PROCESS FOR THE PREPARATION OF 2-{2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY}ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA FARMACEUTISK FABRIK (DK) | 2000-09-08 | — | — | WO | disclosed |
| EP-0801064-A1 | Process for the preparation of 2-(2-(4((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-acetic acid and their salts | U C B, S.A. (BE) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258684-A1 | 2-[2-[4-[(4-chlorophenyl) phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride as anti-allergenic compound and process for its production | CMA1, HRH2, HRH1 | DRD3 4061/4885HRH1 3/4885KCNH2 680/4885 |
| US-20030092911-A1 | Hydrolysis in presence of phase transfer agents; antiallergens | CMA1, NAT1, CPN1 | DRD3 2986/4885HRH1 8/4885KCNH2 2290/4885 |
| US-20110172425-A1 | NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES | ALK, WIZ, HACL2 | DRD3 1114/4885HRH1 1046/4885KCNH2 111/4885 |
| US-20160367551-A1 | COMPLEX GRANULE FORMULATION HAVING IMPROVED STABILITY COMPRISING LEVOCETIRIZINE AND MONTELUKAST | GRK5, CMA1, TAS2R14 | DRD3 2887/4885HRH1 450/4885KCNH2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.